Kim Brownell, MD Medical Director Hartford HealthCare Behavioral Health Network Hartford, Connecticut
Dana Sinopoli, PsyD Licensed psychologist Private practice Philadelphia, Pennsylvania
Karlyn Huddy, MD Cardiologist EvergreenHealth Kirkland, Washington
Amy Taylor, MD Inpatient Attending Psychiatrist Institute of Living Hartford, Connecticut
aAt the time this article was written, Dr. Sinopoli was a postdoctoral resident in the psychology department, and Dr. Huddy was a Cardiology Fellow at Hartford Hospital’s The Institute of Living in Hartford, Connecticut.
Follow-up appointment with cardiology and repeat echocardiography were scheduled for 6 weeks after discharge. The follow-up echocardiogram showed improvement (LVEF, 50%). Mr. C continues to do well and remains a client at the IOP program.
Bottom Line Clozapine often is used as a last resort for patients with treatment-resistant schizophrenia, but its side-effect profile requires careful management and monitoring. If a patient taking clozapine shows tachycardia, consider cardiomyopathy. Evaluation might include lab testing, electrocardiography, and echocardiography. Symptoms often resolve when clozapine is discontinued.
Related Resources • Citrome L. Clozapine for schizophrenia: life-threatening or life-saving treatment? Current Psychiatry. 2009;8(12):56-63. • Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust. 2009;190(4):190-192.
Disclosure The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.